Inmune Bio, Inc. financial data

Symbol
INMB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
225 Ne Mizner Blvd, Suite 640, Boca Raton, FL
State of incorporation
NV
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 231 % -33.4%
Debt-to-equity 40.5 % +1.61%
Return On Equity -46.3 %
Return On Assets -87.8 % -92.8%
Operating Margin -26.2K % -152%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22.9M shares +27.2%
Common Stock, Shares, Outstanding 22.3M shares +24.1%
Entity Public Float 135M USD +27.4%
Common Stock, Value, Issued 22K USD +22.2%
Weighted Average Number of Shares Outstanding, Basic 19.9M shares +10.9%
Weighted Average Number of Shares Outstanding, Diluted 19.9M shares +10.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 131K USD -47.4%
Research and Development Expense 33.2M USD +63.6%
General and Administrative Expense 9.48M USD -1.46%
Operating Income (Loss) -42.6M USD -43.4%
Nonoperating Income (Expense) 193K USD
Net Income (Loss) Attributable to Parent -42.1M USD -40.2%
Earnings Per Share, Basic -2.11 USD/shares -26.3%
Earnings Per Share, Diluted -2.11 USD/shares -26.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.9M USD -41.6%
Accounts Receivable, after Allowance for Credit Loss, Current 1.18M USD -38%
Assets, Current 22.7M USD -43.3%
Operating Lease, Right-of-Use Asset 307K USD -25.8%
Intangible Assets, Net (Excluding Goodwill) 16.5M USD 0%
Other Assets, Noncurrent 79K USD -39.7%
Assets 39.6M USD -30.6%
Liabilities, Current 7.22M USD -60.9%
Operating Lease, Liability, Noncurrent 244K USD -38.5%
Liabilities 7.47M USD -60.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -575K USD +28%
Retained Earnings (Accumulated Deficit) -163M USD -34.8%
Stockholders' Equity Attributable to Parent 32.1M USD -14%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 50.7M USD -27.6%
Liabilities and Equity 39.6M USD -30.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.48M USD -555%
Net Cash Provided by (Used in) Financing Activities -2.5M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 22.3M shares +24.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.85M USD -756%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 20.9M USD -41.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 302K USD -32.9%
Deferred Tax Assets, Valuation Allowance 25.7M USD +31%
Deferred Tax Assets, Gross 25.7M USD +31.1%
Operating Lease, Liability 384K USD -25.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -41.9M USD -39%
Lessee, Operating Lease, Liability, to be Paid 442K USD -29.6%
Operating Lease, Liability, Current 140K USD +17.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 198K USD +2.59%
Lessee, Operating Lease, Liability, to be Paid, Year One 193K USD +3.76%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 58K USD -48.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 51K USD -74.2%
Deferred Tax Assets, Operating Loss Carryforwards 8.69M USD +26.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 51K USD
Additional Paid in Capital 196M USD +23%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 545K USD
Share-based Payment Arrangement, Expense 1.72M USD -9%
Interest Expense 789K USD -65.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%